Pharmaceutical formulation comprising between 100 - 150 mg / ml of an Antibody that specifically binds to the Receptor of Human il-17, an aqueous solution of a buffer 5 - 30 mm glutamic acid pH 4,5 - 5.2, Proline 2 - 4% p / V and Polysorbate 20 0005 - 0.02% p / V； Pharmaceutical Packaging and kit comprising such formulation； and its use to treat psoriasis.
LIU DINGIIANG,MARTIN DAVID ANDREW,RUSSELL CHRISTOPHER BOYD,SALINGER DAVID H,BAUMGARTNER SCOTT WALTER,HUANG HOLLY ZHUOHOONG,ENDRES CHRISTOPHER J
申请号：
CL2012001966
公开号：
CL2012001966A1
申请日:
2012.07.13
申请国别(地区):
CL
年份:
2013
代理人:
摘要：
Pharmaceutical formulation comprising between 100 - 150 mg / ml of an Antibody that specifically binds to the Receptor of Human il-17, an aqueous solution of a buffer 5 - 30 mm glutamic acid pH 4,5 - 5.2, Proline 2 - 4% p / V and Polysorbate 20 0005 - 0.02% p / V； Pharmaceutical Packaging and kit comprising such formulation； and its use to treat psoriasis.<；p>；Formulació；n farmacé；utica que comprende entre 100-150 mg/ml de un anticuerpo que se une especí；ficamente al receptor a de IL-17 humana, una solució；n acuosa de un buffer 5-30 mm de á；cido glutá；mico PH 4,5-5,2, prolina 2-4% P/V y polisorbato-20 0,005-0,02% P/V； envase farmacé；utico y kit que comprende dicha formulació；n； y su uso para tratar psoriasis.<；/p>；
